AR099400A1 - Compuesto heterocíclico fusionado - Google Patents

Compuesto heterocíclico fusionado

Info

Publication number
AR099400A1
AR099400A1 ARP150100411A ARP150100411A AR099400A1 AR 099400 A1 AR099400 A1 AR 099400A1 AR P150100411 A ARP150100411 A AR P150100411A AR P150100411 A ARP150100411 A AR P150100411A AR 099400 A1 AR099400 A1 AR 099400A1
Authority
AR
Argentina
Prior art keywords
substituted
heterocyclic compound
fused heterocyclic
optionally substituted
group
Prior art date
Application number
ARP150100411A
Other languages
English (en)
Spanish (es)
Inventor
Ikeda Zenichi
Nishikawa Yoichi
Sasaki Minoru
Kakegawa Keiko
Kikuchi Fumiaki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of AR099400A1 publication Critical patent/AR099400A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
ARP150100411A 2014-02-13 2015-02-12 Compuesto heterocíclico fusionado AR099400A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014025832 2014-02-13

Publications (1)

Publication Number Publication Date
AR099400A1 true AR099400A1 (es) 2016-07-20

Family

ID=52589729

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100411A AR099400A1 (es) 2014-02-13 2015-02-12 Compuesto heterocíclico fusionado

Country Status (41)

Country Link
US (2) US9346776B2 (enExample)
EP (1) EP3105213B1 (enExample)
JP (2) JP6383427B2 (enExample)
KR (1) KR102378454B1 (enExample)
CN (1) CN105980370B (enExample)
AR (1) AR099400A1 (enExample)
AU (1) AU2015216438B2 (enExample)
BR (1) BR112016018455B1 (enExample)
CA (1) CA2938191C (enExample)
CL (1) CL2016001911A1 (enExample)
CR (1) CR20160367A (enExample)
CY (1) CY1121534T1 (enExample)
DK (1) DK3105213T3 (enExample)
DO (1) DOP2016000206A (enExample)
EA (1) EA032201B1 (enExample)
EC (1) ECSP16067137A (enExample)
ES (1) ES2717113T3 (enExample)
GE (1) GEP20176808B (enExample)
HR (1) HRP20190369T1 (enExample)
HU (1) HUE042709T2 (enExample)
IL (1) IL246838B (enExample)
JO (1) JO3472B1 (enExample)
LT (1) LT3105213T (enExample)
MA (1) MA39246A1 (enExample)
ME (1) ME03422B (enExample)
MX (1) MX368392B (enExample)
MY (1) MY173607A (enExample)
NZ (1) NZ722035A (enExample)
PE (1) PE20161243A1 (enExample)
PH (1) PH12016501582B1 (enExample)
PL (1) PL3105213T3 (enExample)
PT (1) PT3105213T (enExample)
RS (1) RS58498B1 (enExample)
SG (1) SG11201605654QA (enExample)
SI (1) SI3105213T1 (enExample)
SM (1) SMT201900175T1 (enExample)
TR (1) TR201903892T4 (enExample)
TW (1) TWI669297B (enExample)
UA (1) UA118280C2 (enExample)
UY (1) UY35994A (enExample)
WO (1) WO2015122187A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2975023T (lt) * 2013-03-13 2018-08-10 Takeda Pharmaceutical Company Limited Guanidinbenzoinės rūgšties esterio junginys
PE20161573A1 (es) 2014-02-13 2017-01-19 Incyte Corp Ciclopropilamina como inhibidor de la lsd1
US9493450B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
JP2018080109A (ja) * 2015-03-16 2018-05-24 武田薬品工業株式会社 治療剤
JP6634070B2 (ja) * 2015-03-27 2020-01-22 武田薬品工業株式会社 縮合複素環化合物
PE20180455A1 (es) 2015-04-03 2018-03-05 Incyte Corp Compuestos heterociclicos como inhibidores de lsd1
SG10202001219UA (en) 2015-08-12 2020-03-30 Incyte Corp Salts of an lsd1 inhibitor
CN111542511A (zh) * 2017-11-02 2020-08-14 宇部兴产株式会社 蛋白分解酶的双头型抑制剂
UA126099C2 (uk) 2018-05-09 2022-08-10 ЕлДжи КЕМ, ЛТД. Сполука, яка виявляє інгібувальну активність відносно ентеропептидази
JP6773938B2 (ja) * 2018-08-27 2020-10-21 株式会社スコヒアファーマ 安息香酸エステル化合物
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
WO2021013742A1 (en) 2019-07-19 2021-01-28 Janssen Pharmaceutica Nv 5,8-disubstituted-[1,2,4]triazolo[1,5-a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives useful as inhibitors of enteropeptidase
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物
WO2021166899A1 (ja) * 2020-02-17 2021-08-26 宇部興産株式会社 インクレチン様物質と組み合わせて使用するための消化管プロテアーゼ阻害剤を含む薬剤
CN111544599B (zh) * 2020-07-10 2020-12-01 有术肌肤管理(深圳)有限公司 一种用于治疗痤疮的化合物及其用于制备药物或化妆品的用途
CN111803652B (zh) * 2020-08-04 2021-09-14 南通康是美生物科技有限公司 治疗痤疮的化合物在制备治疗痤疮的药物组合物或化妆品组合物中的用途
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
TW202532060A (zh) * 2023-12-01 2025-08-16 日商Ea製藥股份有限公司 醫藥組成物
WO2025115989A1 (ja) * 2023-12-01 2025-06-05 Eaファーマ株式会社 医薬組成物
WO2025211248A1 (ja) * 2024-04-04 2025-10-09 Eaファーマ株式会社 医薬組成物

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5289640A (en) 1976-01-21 1977-07-27 Ono Pharmaceut Co Ltd Guanidinobenzoic acid derivatives, and antiplasmin agents and remedies for pancreas diseases containing the said guanidinobensolc acid deriv atives
JPS5753454A (en) 1980-09-16 1982-03-30 Torii Yakuhin Kk Guanidinobenzoate and anticomplementary agent
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
JP2886586B2 (ja) 1989-12-28 1999-04-26 雪印乳業株式会社 新規グアニジノ安息香酸誘導体及びその酸付加塩
US5116985A (en) 1989-12-28 1992-05-26 Snow Brand Milk Products Co., Ltd. Isoquinoline derivatives and salts thereof
JPH0446148A (ja) 1990-06-08 1992-02-17 Asahi Chem Ind Co Ltd 4―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤
JPH06192085A (ja) 1992-08-31 1994-07-12 Yuji Inada ダニアレルギー治療剤
WO1994013631A1 (fr) 1992-12-10 1994-06-23 Teikoku Chemical Industries Co., Ltd. Derive d'acide proprionique
JPH0753500A (ja) 1993-08-16 1995-02-28 Sanwa Kagaku Kenkyusho Co Ltd グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤
JPH0848664A (ja) 1994-08-05 1996-02-20 Hisamitsu Pharmaceut Co Inc 新規なグアニジノ安息香酸エステル誘導体
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
JPH09124571A (ja) 1995-11-01 1997-05-13 Japan Tobacco Inc アミド化合物及びその用途
US6388122B1 (en) 1996-04-10 2002-05-14 Ono Pharmaceutical Co., Ltd. Tryptase inhibitor and novel guanidino derivatives
JPH10101556A (ja) 1996-09-27 1998-04-21 Ono Pharmaceut Co Ltd ファクターd阻害剤
JPH10251239A (ja) 1997-03-14 1998-09-22 Mochida Pharmaceut Co Ltd 新規4h−3,1−ベンゾオキサジン−4−オン誘導体
JPH10306025A (ja) 1997-05-07 1998-11-17 Touin Yokohama Univ 花粉プロテアーゼ阻害剤
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
PL376733A1 (pl) 2002-11-01 2006-01-09 Takeda Pharmaceutical Company Limited Środek do zapobiegania lub leczenia neuropatii
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
EP1695961A4 (en) 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
AU2004309271A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
US7585880B2 (en) 2003-12-26 2009-09-08 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
EP1726580A4 (en) 2004-03-15 2008-02-13 Takeda Pharmaceutical AMINOPHNYLPROPANO ACID DERIVATIVE
EP1731505B1 (en) 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US7671057B2 (en) 2004-11-08 2010-03-02 Ono Pharmaceutical Co., Ltd. Therapeutic agent for type II diabetes comprising protease-inhibiting compound
EP1843819A2 (en) 2004-11-15 2007-10-17 Obe Therapy Biotechnology S.A.S. Methods of reducing body fat
US20080274945A1 (en) 2004-11-26 2008-11-06 N.V. Nutricia Infant Nutrition With Protease Inhibitor
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
JP2006348023A (ja) * 2005-05-17 2006-12-28 Santen Pharmaceut Co Ltd アミン誘導体を有効成分として含む血管新生阻害剤
JPWO2007013694A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 フェノキシアルカン酸化合物
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
CA2617969A1 (en) 2005-08-10 2007-02-15 Takeda Pharmaceutical Company Limited Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2007208495A1 (en) * 2006-01-12 2007-08-02 Merck Sharp & Dohme Corp. Hydroxyalkylarylamide derivatives
ES2379661T3 (es) 2006-06-27 2012-04-30 Takeda Pharmaceutical Company Limited Compuestos cíclicos condensados
JP5306818B2 (ja) 2006-10-18 2013-10-02 武田薬品工業株式会社 縮合複素環化合物
US8410087B2 (en) 2006-10-19 2013-04-02 Takeda Pharmaceutical Company Limited Indole compound
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
CA2677736A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素5員複素環化合物
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
EP2225261B1 (en) 2007-12-03 2016-03-09 Obe Therapy Biotechnology Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism
CN102822154B (zh) 2009-12-07 2016-06-01 味之素株式会社 杂芳基羧酸酯衍生物
WO2012169579A1 (ja) 2011-06-07 2012-12-13 味の素株式会社 ヘテロ環カルボン酸エステル誘導体
PH12014500573A1 (en) 2011-09-15 2014-04-14 Astellas Pharma Inc Guanidinobenzoic acid compound
US10398762B2 (en) 2012-01-03 2019-09-03 Oramed Ltd. Methods and compositions for treating diabetes
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
EP2941267B1 (en) 2013-01-03 2022-11-16 Oramed Ltd. Compositions for use in treating nafld
JP6374889B2 (ja) 2013-03-08 2018-08-15 アムジエン・インコーポレーテツド β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合1,3−オキサジン−2−アミン化合物、及び使用方法
LT2975023T (lt) * 2013-03-13 2018-08-10 Takeda Pharmaceutical Company Limited Guanidinbenzoinės rūgšties esterio junginys
SMT202000071T1 (it) 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9493450B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
PE20161573A1 (es) 2014-02-13 2017-01-19 Incyte Corp Ciclopropilamina como inhibidor de la lsd1
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound

Also Published As

Publication number Publication date
HUE042709T2 (hu) 2019-07-29
JP2018197254A (ja) 2018-12-13
SG11201605654QA (en) 2016-08-30
EP3105213A1 (en) 2016-12-21
ES2717113T3 (es) 2019-06-19
JP6383427B2 (ja) 2018-08-29
UY35994A (es) 2015-08-31
ME03422B (me) 2020-01-20
TW201607936A (zh) 2016-03-01
PL3105213T3 (pl) 2019-06-28
CA2938191C (en) 2021-08-31
NZ722035A (en) 2022-02-25
MA39246A1 (fr) 2018-05-31
PE20161243A1 (es) 2016-11-24
IL246838A0 (en) 2016-08-31
WO2015122187A1 (en) 2015-08-20
CR20160367A (es) 2016-12-01
EA201691619A1 (ru) 2017-01-30
ECSP16067137A (es) 2017-08-31
AU2015216438A1 (en) 2016-07-21
US20160355494A1 (en) 2016-12-08
PH12016501582A1 (en) 2017-02-06
KR20160116002A (ko) 2016-10-06
CA2938191A1 (en) 2015-08-20
UA118280C2 (uk) 2018-12-26
DK3105213T3 (en) 2019-04-15
MX2016010559A (es) 2016-11-16
CL2016001911A1 (es) 2017-02-10
EP3105213B1 (en) 2019-01-09
JO3472B1 (ar) 2020-07-05
BR112016018455B1 (pt) 2022-09-06
SMT201900175T1 (it) 2019-05-10
KR102378454B1 (ko) 2022-03-23
RS58498B1 (sr) 2019-04-30
MX368392B (es) 2019-10-01
PT3105213T (pt) 2019-04-16
HRP20190369T1 (hr) 2019-05-03
EA032201B1 (ru) 2019-04-30
LT3105213T (lt) 2019-03-12
AU2015216438B2 (en) 2018-12-06
BR112016018455A2 (en) 2018-05-08
GEP20176808B (en) 2018-01-10
CN105980370B (zh) 2018-03-02
TWI669297B (zh) 2019-08-21
IL246838B (en) 2020-01-30
JP6529649B2 (ja) 2019-06-12
US9346776B2 (en) 2016-05-24
US20150225361A1 (en) 2015-08-13
PH12016501582B1 (en) 2019-03-13
DOP2016000206A (es) 2018-01-31
JP2017506627A (ja) 2017-03-09
SI3105213T1 (sl) 2019-05-31
US9969705B2 (en) 2018-05-15
CN105980370A (zh) 2016-09-28
TR201903892T4 (tr) 2019-04-22
CY1121534T1 (el) 2020-05-29
MY173607A (en) 2020-02-10

Similar Documents

Publication Publication Date Title
AR099400A1 (es) Compuesto heterocíclico fusionado
PT3883936T (pt) Novos compostos heterocíclicos
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
MA46188A (fr) Composés indole substitués par pyridyle
EP3896060A4 (en) HETEROCYCLIC COMPOUND
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
EP3895707A4 (en) HETEROCYCLIC COMPOUND
UY36315A (es) COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.
AR101367A1 (es) Pirimidinonas como inhibidores del factor xia
EP3438109A4 (en) HETEROCYCLIC CONNECTION
EP3498693A4 (en) HETEROCYCLIC CONNECTION
AR099677A1 (es) Compuesto heterocíclico fusionado y su uso para el control de plagas
CR20150509A (es) Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina
EA201600091A1 (ru) 4-членные кольцевые карбоксамиды, применяемые в качестве нематоцидов
AR097866A1 (es) Derivados de 4-azaindol
EA201791684A1 (ru) Селективные ингибиторы bace1
AR095523A1 (es) Derivados piridin-4-ilo
AR106486A1 (es) Antagonistas de receptores de cgrp
EA201790983A1 (ru) Синтез копанлисиба и его дигидрохлорида
EP3444239A4 (en) Heterocyclic compound
EA201892449A1 (ru) Конденсированные гетероциклические соединения
EP3424905A4 (en) HETEROCYCLIC CONNECTION
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
MA47129A (fr) Sel de composé pipéridine substitué
AR100439A1 (es) Derivados de carboxamida

Legal Events

Date Code Title Description
FG Grant, registration